OÄ Dr. Ursula Vogl
ESMO 2019: RCC – „Abwarten, was Immuntherapie im adjuvanten Setting bringt“
OÄ Dr. Ursula Vogl, Barmherzige Schwestern Krankenhaus Wien, über Rückschritte bei der adjuvanten Behandlung und bereits erprobte und neue Ansätze im metastasierten Setting.
Im Video diskutierte Abstracts:
Eisen TQ et al. Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL. #LBA56
Lee CH et al. ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC). #LBA54
Grimm MO et al. Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC). #LBA57
Lee CH et al. Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis. #1187PD
McDermott DF et al. Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment. #1186PD